GlassScriptPhysician profile
Thomas T Ton
NPI 1912018789
$13,710.88
in general payments reported to CMS, 2019-2025
29 companies · $1,830 in 2025
The $1,830 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,789 · 2020: $1,505 · 2021: $799 · 2022: $970 · 2023: $1,330 · 2024: $1,488 · 2025: $1,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,648.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,309.27 | 2019-2025 | Repatha, Evenity, Otezla |
| Gilead Sciences, INC. | $1,893.68 | 2019-2025 | Vemlidy, Epclusa |
| Astrazeneca Pharmaceuticals LP | $1,104.19 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,073.97 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $990.05 | 2019-2025 | Taltz |
| Abbvie INC. | $806.71 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $559.70 | 2019 | |
| Phathom Pharmaceuticals, INC. | $506.21 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $353.01 | 2019-2023 | Ocaliva |
| Inari Medical, INC. | $269.51 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Aimmune Therapeutics, INC. | $249.72 | 2025 | Zenpep |
| Allergan, INC. | $246.29 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $246.07 | 2025 | |
| Novartis Pharmaceuticals Corporation | $243.81 | 2019 | |
| Amarin Pharma, INC. | $234.86 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $159.13 | 2025 | Freestyle Libre 3 |
| Genzyme Corporation | $144.82 | 2025 | |
| Theratechnologies INC. | $125.01 | 2019 | |
| Vanda Pharmaceuticals INC. | $125.00 | 2025 | Fanapt |
| Ardelyx, INC. | $125.00 | 2024 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Novo Nordisk INC | $124.67 | 2020 | |
| Glaxosmithkline, LLC. | $122.31 | 2025 | Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $119.73 | 2019 | |
| Bard Peripheral Vascular, INC. | $119.19 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.00 | 2019 | |
| Merck Sharp & Dohme LLC | $105.93 | 2019 | |
| Horizon Therapeutics Plc | $104.02 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.